Vis enkel innførsel

dc.contributor.authorKummen, Martin
dc.contributor.authorSolberg, Ole Geir
dc.contributor.authorLarsen, Christopher Storm
dc.contributor.authorHolm, Kristian
dc.contributor.authorRagnarsson, Asgrimur
dc.contributor.authorTrøseid, Marius
dc.contributor.authorVestad, Beate
dc.contributor.authorSkårdal, Rita
dc.contributor.authorYndestad, Arne
dc.contributor.authorUeland, Thor
dc.contributor.authorSvardal, Asbjørn M.
dc.contributor.authorBerge, Rolf Kristian
dc.contributor.authorSeljeflot, Ingebjørg
dc.contributor.authorGullestad, Lars
dc.contributor.authorKarlsen, Tom Hemming
dc.contributor.authorAaberge, Lars
dc.contributor.authorAukrust, Pål
dc.contributor.authorHov, Johannes Espolin Roksund
dc.PublishedScientific Reports. 2020, 10:5397 1-9.
dc.description.abstractThe gut microbiome contributes to the variation of blood lipid levels, and secondary bile acids are associated with the effect of statins. Yet, our knowledge of how statins, one of our most common drug groups, affect the human microbiome is scarce. We aimed to characterize the effect of rosuvastatin on gut microbiome composition and inferred genetic content in stool samples from a randomized controlled trial (n = 66). No taxa were significantly altered by rosuvastatin during the study. However, rosuvastatin-treated participants showed a reduction in the collective genetic potential to transport and metabolize precursors of the pro-atherogenic metabolite trimethylamine-N-oxide (TMAO, p < 0.01), and an increase of related metabolites betaine and γ-butyrobetaine in plasma (p < 0.01). Exploratory analyses in the rosuvastatin group showed that participants with the least favorable treatment response (defined as < median change in high-density/low-density lipoprotein (HDL/LDL) ratio) showed a marked increase in TMAO-levels compared to those with a more favorable response (p < 0.05). Our data suggest that while rosuvastatin has a limited effect on gut microbiome composition, it could exert broader collective effects on the microbiome relevant to their function, providing a rationale for further studies of the influence of statins on the gut microbiome.en_US
dc.publisherNature Researchen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleRosuvastatin alters the genetic composition of the human gut microbiomeen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright The Author(s) 2020en_US
dc.source.journalScientific Reportsen_US
dc.identifier.citationScientific Reports. 2020, 10, 5397.en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal